Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Concentrating on clots

Although Nuvelo Inc. suspended development of alfimeprase last year when two Phase III trials in different indications missed their endpoints, the company never stopped believing that the thrombolytic works. In the acute peripheral arterial occlusion indication, NUVO thought delivery was to blame, while in the central venous catheter occlusion indication, the data were significant but didn't meet the bar for approval based on a single pivotal study.

Last week, the company

Read the full 706 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE